SGI-7079, a novel selective Axl inhibitor with an IC50 of 58 nM in vitro, inhibits tumor growth in a dose dependent manner and is a potential therapeutic target for overcoming EGFR inhibitor resistance.

SGI-7079, a novel selective Axl inhibitor with an IC50 of 58 nM in vitro, inhibits tumor growth in a dose dependent manner and is a potential therapeutic target for overcoming EGFR inhibitor resistance.

TP-0903 is a potent and selective AXL Inhibitor with IC50 of 27 nM. TP-0903 is highly effective in inducing apoptosis.

TP-0903 is a potent and selective AXL Inhibitor with IC50 of 27 nM. TP-0903 is highly effective in inducing apoptosis.

SirReal2 is a potent and selective Sirt2 inhibitor with IC50 of 140 nM.

SirReal2 is a potent and selective Sirt2 inhibitor with IC50 of 140 nM.

Cyclo(RGDyK) TFA is a salt formed by the combination of Cyclo(RGDyK) and trifluoroacetate (TFA). It is an effective and selective Integrin αvβ3 inhibitor with a low IC50 value (e.g., 20 nM). Cyclo(RGDyK) TFA is of great significance in the treatment of cardiovascular diseases, osteoporosis, inflammation and tumors.

Cyclo(RGDyK) TFA is a salt formed by the combination of Cyclo(RGDyK) and trifluoroacetate (TFA). It is an effective and selective Integrin αvβ3 inhibitor with a low IC50 value (e.g., 20 nM). Cyclo(RGDyK) TFA is of great significance in the treatment of cardiovascular diseases, osteoporosis, inflammation and tumors.

Brilanestrant (GDC-0810, ARN-810） is a potent ER-α binder (ER-α, IC50 = 6.1 nM; ER-β, IC50 = 8.8 nM), a full transcriptional antagonist with no agonism and displays good potency and efficacy in ER-α degradation (EC50 = 0.7 nM) and MCF-7 breast cancer cell viability (IC50 = 2.5 nM) assays with good selectivity over other nuclear […]

Tenofovir Alafenamide is a prodrug of tenofovir, which is a reverse transcriptase inhibitor, used to treat HIV and Hepatitis B.